With strong share price gains and significant hedge fund interest, PTC Inc. (NASDAQ:PTC) secures a spot on our list of the 11 Hot Software Stocks to Buy Now. On July 31, 2025, Barclays lifted its ...
PTC's diversified software suite and high-margin recurring revenue model drive solid fundamentals, despite capability competition from Autodesk and Dassault. Operating margins are expanding, now at ...
PTC Therapeutics reported a phase 2 win for its Novartis-partnered Huntington's disease candidate. But the readout failed to convince investors, who wiped almost 20% off PTC’s share price amid doubts ...
PTC Inc PTC is set to exhibit its latest innovation, Windchill AI, at Hannover Messe 2025, strengthening its position in AI-powered product lifecycle management (PLM). Windchill AI is an AI-powered ...
PTC lowered its headline guidance, but revenue and earnings per share are not the best way to judge progress at the company. The company continues to grow its annual run rate of subscription contracts ...
After 26 years, James “Jim” Heppelmann is retiring from PTC this month, marking the conclusion of his notable tenure with the company, which includes the past 13 years as CEO. Under Heppelmann’s ...
PTC Inc PTC has teamed up with Microsoft MSFT and Volkswagen Group VWAGY to create the Codebeamer Copilot, a generative artificial intelligence (AI)-powered tool designed to bolster software ...
Novartis will partner with PTC Therapeutics to expand the use of PTC’s small molecule splicing platform to develop PTC’s PTC518 Huntington’s disease program and an unspecified number of related ...
PTC Therapeutics’ amyotrophic lateral sclerosis (ALS) prospect has flunked a phase 2 trial, prompting the biotech to drop plans for further development of the drug candidate. The study randomized more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results